Quick Read VanEck Pharmaceutical ETF (PPH) surged 26% over the past year driven by weight-loss drug demand. Eli Lilly and ...

VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings ...

Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms ...

As if giving birth isn’t difficult enough, about 14 million women each year lose a significant amount of blood within 24 hours of delivery — a condition called postpartum hemorrhage (PPH). It’s more ...

“PPH requests appear to have been filed for less than 1% of U.S. applications. Why are applicants foregoing the program? While the program does not require payment of a fee per se, the author proposes ...

Below is Validea's ETF fundamental report for VanEck Pharmaceutical ETF (PPH). The report looks at PPH's exposure to the major investing factors including value, quality, momentum and low volatility.

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund ...